Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrecizumab in Cardiogenic Shock
NCT03989531Phase 3Completed
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of adrecizumab in cardiogenic shock. Started Apr 2019; status: completed.
02
Drugs
adrecizumab
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on NCT03989531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989531.